

Statement of Advice:

**abatacept (Orencia®) 125mg solution for injection (pre-filled syringe)
125mg solution for injection in pre-filled pen
250mg powder for concentrate for solution for infusion (No: 1230/17)**
Bristol-Myers Squibb Pharmaceutical Limited

10 February 2017

ADVICE: in the absence of a submission from the holder of the marketing authorisation

abatacept (Orencia®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

**Chairman Designate
Scottish Medicines Consortium**